Latest News-Innovent Biologics,Inc Mediaroom_Page

Innovent released the results of two clinical studies of IBI311 (an anti-IGF-1R monoclonal antibody) in oral presentations at the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024

ROCKVILLIE, Md. and SUZHOU, China, March 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innoven...

2024-03-07 11:53 3100

Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer

ROCKVILLE, Md. and SUZHOU, China, March 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2024-03-05 13:35 2547

Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia

ROCKVILLE, Md. and SUZHOU, China, March 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2024-03-01 08:00 3377

Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA

ROCKVILLIE, MD. and SUZHOU, China, Feb. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innoven...

2024-02-20 08:22 4076

Innovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China

ROCKVILLE, Md. and SUZHOU, China, Feb. 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2024-02-07 16:35 4795

Innovent Announces Retirement of CFO and Appointment of New CFO

ROCKVILLE, Md. and SUZHOU, China, Feb. 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("c") (HKEX...

2024-02-05 16:45 2990

Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA

ROCKVILLE, Md. and SUZHOU, China, Jan. 9, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2024-01-09 08:00 4036

Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity

ROCKVILLE, Md. and SUZHOU, China, Jan. 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2024-01-02 08:00 9310

Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity

Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China

ROCKVILLE, Md. and SUZHOU, China, Dec. 28, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2023-12-28 08:00 3839

Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension

ROCKVILLE, Md. and SUZHOU, China, Dec. 27, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2023-12-27 08:00 3758

Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension

Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation

ROCKVILLE, Md. and SUZHOU, China, Dec. 19, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2023-12-19 08:00 6798

Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications

ROCKVILLE, Md. and SUZHOU, China, Dec. 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2023-12-18 08:00 6454

Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications

Innovent Announces Inclusion in the China National Reimbursement Drug List of TYVYT® 's Seventh Indication and BYVASDA®'s Eighth Indication

ROCKVILLE, Md. and SUZHOU, China, Dec. 13, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2023-12-13 12:56 3192

Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study

ROCKVILLE, M.D. and SUZHOU, China, Dec. 7, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2023-12-07 09:00 3607

Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

ROCKVILLE, Md. and SUZHOU, China, Dec. 6, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2023-12-06 08:16 3687

Innovent Presents Clinical Data Update of IBI351 (KRAS G12C Inhibitor) Monotherapy in Lung Cancer and Colorectal Cancer at ESMO Asia Congress 2023

ROCKVILLE, Md. and SUZHOU, China, Dec. 1, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2023-12-01 12:00 2434

Innovent's MSCI ESG Rating Upgraded to A

ROCKVILLE, Md. and SUZHOU, China, Nov. 30, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2023-11-30 21:37 7367

Innovent's MSCI ESG Rating Upgraded to A

China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351

ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2023-11-24 08:42 4217

Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Accepted the New Drug Application for Taletrectinib (ROS1 Inhibitor)

ROCKVILLE, Md. and SUZHOU, China, Nov. 23, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2023-11-23 08:00 3453

Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care

ROCKVILLE, Md.and SUZHOU,China, Nov. 22, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (...

2023-11-22 12:40 6297